Skip to main content
. 2022 Nov 16;5(1):e36–e46. doi: 10.1016/S2665-9913(22)00330-7

Figure 3.

Figure 3

Distribution of anti-RBD antibody concentrations across diagnoses and medication groups in the vaccine and hybrid groups

(A) The distribution of anti-RBD antibody concentrations across diagnoses in patients following a series of three and four vaccine doses (vaccine group), and in controls receiving three vaccine doses. (B) The distribution of anti-RBD antibody concentrations across medication groups in patients following a series of three and four vaccine doses (vaccine group), and in controls receiving three doses. (C) The distribution of anti-RBD antibody concentrations across diagnoses in patients with hybrid immunity with COVID-19 following a series of three vaccine doses (hybrid group). (D) The distribution of anti-RBD antibody concentrations across medication groups in patients with hybrid immunity with COVID-19 following a series of three vaccine doses (hybrid group). Violin plot of probability densities, smoothed by a kernel density estimator. Points denote participants, and solid black lines show group medians. Anti-RBD antibody concentrations after the third vaccine dose are marked in light blue, and after the fourth dose (vaccine group) or COVID-19 infection (hybrid group) in red. Anti-RBD antibody concentrations after the third vaccine dose in the control group are shown to the left. RBD=receptor binding domain.